Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)

被引：7
|
作者：
Badros, Ashraf Z. [1 ]
Hyjek, Elizabeth [2 ]
Ma, Ning [1 ]
Lesokhin, Alexander M. [3 ]
Rapoport, Aaron P. [1 ]
Kocoglu, Mehmet H. [1 ]
Lederer, Emily [4 ]
Philip, Sunita [4 ]
Lesho, Patricia [4 ]
Johnson, Ashlee [4 ]
Dell, Cameron [4 ]
Goloubeva, Olga [4 ]
Singh, Zeba [5 ]
机构：
[1] Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD USA
[2] Univ Chicago, Dept Pathol, Chicago, IL USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, Myeloma Serv, New York, NY USA
[4] Univ Maryland, Baltimore, MD USA
[5] Univ Maryland, Sch Med, Pathol, Baltimore, MD USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.490.490
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
490
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Preliminary Results From a Phase Ib Study of Isatuximab in Combination with Pomalidomide (Pom) and Dexamethasone (Dex) in Relapsed and Refractory Multiple Myeloma (RRMM)
    Richardson, Paul
    Mikhael, Joseph
    Usmani, Saad
    Raje, Napoor
    Bensinger, William
    Campana, Frank
    Gao, Lei
    Dubin, Franck
    Wack, Claudine
    Anderson, Kenneth C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E16 - E17
  • [22] Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
    Shah, Jatin
    Usmani, Saad
    Stadtmauer, Edward A.
    Rifkin, Robert M.
    Berenson, James R.
    Berdeja, Jesus G.
    Lyons, Roger M.
    Klippel, Zandra
    Chang, Yu-Lin
    Niesvizky, Ruben
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (09): : 570 - +
  • [23] POMALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PREVIOUSLY TREATED WITH LENALIDOMIDE
    Gomez, Hernando Marta
    Gironella, Merce
    Abella, Eugenia
    Cabezudo, Elena
    Motllo, Cristina
    Garcia, Antoni
    Sarra, Josep
    Mostacedo, Silvia
    Granell, Miquel
    Rosinol, Laura
    HAEMATOLOGICA, 2020, 105 : 13 - 14
  • [24] A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183.
    Mateos, Maria-Victoria
    Blacklock, Hilary
    Schjesvold, Fredrik
    Rocafiguera, Albert Oriol
    Simpson, David
    George, Anupkumar
    Goldschmidt, Hartmut
    Larocca, Alessandra
    Sherbenou, Daniel Wayne
    Avivi, Irit
    Iida, Shinsuke
    Matsumoto, Morio
    Usmani, Saad Zafar
    Jagannath, Sundar
    Rodriguez-Otero, Paula
    Kher, Uma
    Farooqui, Mohammed Z. H.
    Liao, Jason
    Marinello, Patricia
    Lonial, Sagar
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] Novel combination immunotherapy for relapsed/refractory multiple myeloma (RRMM): initial Phase 1 safety run-in results for cevostamab in combination with pomalidomide and dexamethasone
    Jelinek, Tomas
    Spencer, Andrew
    Krishnan, Amrita
    Trudel, Suzanne
    Harrison, Simon
    Breuleux, Madlaina
    Goodman, Grant
    Huang, Jiangeng
    Mishra, Ameet
    Richardson, Leanne
    Tsai, Jennifer
    Vij, Ravi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S43 - S43
  • [26] PANOBINOSTATPK/PD IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITHRELAPSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).
    Mu, S.
    Tajima, T.
    Corrado, C.
    Sunami, K.
    Suzuki, K.
    Hino, M.
    Kuroda, Y.
    Shibayama, H.
    Lin, R.
    Waldron, E.
    Binlich, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S49 - S49
  • [27] Efficacy and safety of 40 mg vs 60 mg once weekly selinexor in combination with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (RRMM)
    White, Darrell
    Schiller, Gary J.
    Madan, Sumit
    Lentzsch, Suzanne
    Chubar, Evgeni
    Lavi, Noa
    Van Domelen, Dane R.
    Bentur, Ohad S.
    Baljevic, Muhamed
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
    Trudel, Suzanne
    McCurdy, Arleigh
    Sutherland, Heather J.
    Louzada, Martha L.
    Venner, Christopher P.
    Mian, Hira S.
    Kotb, Rami
    Othman, Ibraheem
    Camacho, Fernando
    Gul, Engin
    Reece, Donna E.
    White, Darrell J.
    Fu, Molei
    BLOOD, 2021, 138
  • [29] A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra A.
    Mann, Mason L.
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD, 2019, 134
  • [30] Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis.
    Mateos, Maria-Victoria
    Orlowskit, Robert Z.
    Siegel, David Samuel DiCapua
    Reece, Donna Ellen
    Moreau, Philippe
    Ocio, Enrique M.
    Shah, Jatin J.
    Rodriguez-Oterot, Paula
    Munshi, Nikhil C.
    Avigan, David
    Ge, Joy Yang
    Marinello, Patricia Maria
    Miguel, Jesus San
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345